Panminerva medica, 53 (3 Suppl 1), 65-70
Third, BPC-157 is a genuine outlier, its gastric stability gives it unusually high absorption across all oral routes
5/5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg BPC-157 + 2,500 mcg TB-500 per mL 250 mcg dose (of each) = 10 units (0.1 mL) on a 100-unit insulin syringe 500 mcg dose (of each) = 20 units (0.2 mL) on a 100-unit insulin syringe Doses per vial: 20 doses at 250 mcg each, or 10 doses at 500 mcg each Supplies Needed (4-Week Loading at 500 mcg/day) 3 vials BPC-157/TB-500 blend (5/5 mg each) provides 30 doses at 500 mcg, covers 28 days with margin 3 vials bacteriostatic water (30 mL each) 30 insulin syringes (2931 gauge, 100-unit) Alcohol prep pads Administration Injection Technique Standard subcutaneous injection
Eur J Endocrinol 173(6):791799
Early Trials in GI Disorders: The originators of BPC-157 in Europe conducted some early-phase trials in the late 1990s and early 2000s on patients with ulcerative colitis (an inflammatory bowel disease)
Dosing & Reconstitution Guide Educational guide for reconstitution and daily dosing Standard / Gradual Approach (3 mL = ~3.33 mg/mL) Route: Subcutaneous injection, once daily [5] [6]